Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
REVENUE:
Total revenue	$ 122		$ 455	$ 10,660
COSTS AND EXPENSES:
Research and development	14,828	$ 10,785	37,049	38,602
General and administrative	15,037	4,710	34,683	15,585
Total costs and expenses	29,865	15,495	71,732	54,187
LOSS FROM OPERATIONS	(29,743)	(15,495)	(71,277)	(43,527)
OTHER (EXPENSE) INCOME, NET:
Interest income	1,357	392	2,572	1,020
Change in fair value of warrant liabilities	(40,184)	(27,277)	(80,845)	(39,611)
Other (expense) income, net	(21)	10	(81)	34
Total other expense, net	(38,848)	(26,875)	(78,354)	(38,557)
Net loss	$ (68,591)	$ (42,370)	$ (149,631)	$ (82,084)
Net loss per share attributable to common stockholders - basic	$ (0.48)	$ (0.47)	$ (1.09)	$ (1.09)
Net loss per share attributable to common stockholders - diluted	$ (0.48)	$ (0.47)	$ (1.09)	$ (1.09)
Weighted-average common stock outstanding - basic (in shares)	144,345,781	90,669,969	137,893,249	75,482,234
Weighted-average common stock outstanding - diluted (in shares)	144,345,781	90,669,969	137,893,249	75,482,234
License
REVENUE:
Total revenue				$ 10,660
Research and development services
REVENUE:
Total revenue	$ 122		$ 455

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Name:	us-gaap_EarningsPerShareBasic
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.